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Abstract
In this chapter, we review the history of HCV infection in patients with liver cirrhosis.
Selection of appropriate regimens for HCV-infected patients with cirrhosis, consistent
with approved indications, practice guidelines, and emerging data is presented. Finally,
this chapter explains individualization of therapy to maximize SVR rates in HCV-infected
patients with cirrhosis and to critically appraise the role of newer agents and regimens in
the management of HCV-infected patients with cirrhosis.
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1. Introduction
Hepatitis C virus (HCV) is the leading cause of liver cirrhosis and hepatocellular carcinoma
(HCC) [1]. It remains the main indication for liver transplantation in North America and Europe
[2]. The indication for liver transplantation has changed in the past two decades where NASH
surpasses HBV to become the second most common cause of liver transplantation but HCV
remains unchanged.
Chronic hepatitis C infection in patients with cirrhosis escalates the chances of developing
severe liver-related complications, including hepatic decompensation, hepatocellular cancer
and subsequently, death. It is been a matter of large debate whether to treat cirrhotic patients
and what could be the potential benefit as cirrhosis is irreversible. However, multiple studies
have shown that successful treatment of hepatitis C in patients with compensated cirrhosis
will decrease subsequent cirrhosis-related complications.
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HCV causes increased mortality compared to any other infection; therefore, both the American
Association for the Study of the Liver (AASLD) and European Association for the Study of the
Liver (EASL) guidelines recommend that treatment be indicated for all HCV-infected patients.
However, due to outrageously high cost of the new directly acting antivirals (DAA), treating
every HCV-infected patient is not practical even in countries with strong economy.
Given the high cost of the medications for HCV, both AASLD and EASL guidelines prioritize
the treatment for specific population with liver cirrhosis among the top list.
The goal of HCV treatment in patients with liver cirrhosis depends on the stage of disease. For
Child’s class A compensated liver cirrhosis, the goal of treatment is to prevent progression or
to reverse cirrhosis [3] and to decrease the prevalence of HCC [4–6].
The goal in decompensated liver cirrhosis is to reverse decompensation, delisting from the
liver transplant waiting list or preventing the disease recurrence after liver transplantation [7–
9]. More importantly, achieving sustained virological response (SVR) was associated with
reduced all-cause mortality in patients with advanced fibrosis related to HCV [6].
Several studies have shown reversal of cirrhosis, delisting from liver transplant waiting liver,
improvement of liver function and decrease the risk of HCC in patients who achieved SVR.
Decrease in model for end-stage liver disease (MELD) due to biochemical improvement
without resolution of ascites may delay the liver transplantation by lowering the patient’s rank
on the liver transplant waiting list.
There are also studies showing prevention of disease recurrence after liver transplantation on
those who achieved SVR before liver transplantation.
We predict NASH to be the leading cause of liver transplant in the next decade, not only
because of the growing obesity epidemic and increasing rate of diabetes, but because of the
predicted long-term effect of HCV treatment.
The HCV treatment has evolved since the introduction of Interferon monotherapy in early 1990
until having several options of highly effective interferon-free DAA.
The first randomized multicentre trial comparing interferon alfa-2b versus no treatment in
compensated HCV cirrhosis did not show benefit, whoever, it was small in number, have high
drop-out rate and did not evaluate the patients who achieved sustained virological response
(SVR) well but established safety [10]. In the same year, a study showed that patients with
chronic hepatitis C who have an SVR to IFN therapy, there is a dramatic effect on normalization
of ALT levels, improvement of histological activity and slowing of fibrosis progression [11].
From 2000 to 2011, the combination of PEG-IFN/RBV became the standard of care for HCV
treatment, the overall SVR is 40–50% in genotypes 1 and 4 and 70–80% in genotypes 2 and 3;
however, the SVR rate was significantly lower in patients with liver cirrhosis, about 22% for
genotypes 1 and 4, and 55% for genotypes 2 and 3 [12–14].
Treating patients with decompensated HCV cirrhosis was challenging, it is associated with
poor tolerance, higher side effect profile, and lower SVR rate. Everson and co-workers reported
the results of a low-accelerating dose regimen of IFN or PEG-IFN with RBV in 124 patients
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with decompensated cirrhosis. The SVR was 24%, it was significantly lower in patients with
genotype 1 (13%) than in those with non-1 genotype (50%); (P < 0.0001). SVR was highly
predictive of maintaining viral clearance after liver transplant [8].
Forns et al. evaluated the treatment with IFN a-2b/RBV in 30 patients awaiting Orthotopic liver
transplant (OLT) [9]. A virological response was observed in nine patients (30%). After LT, six
of them (20%) remained negative after liver transplantation.
The study by Carrion et al. evaluated PEG-IFN/RBV therapy in 51 patients with HCV and
cirrhosis awaiting LT matched with 51 untreated controls [15]. The aim of this study is to
evaluate both the prevention of post-transplantation recurrent HCV and the risk of bacterial
infections during therapy. Only 15 patients (29%) were HCV RNA-negative at transplantation
and 10 (20%) achieved an SVR after transplantation.
There is major safety concern of PEG-IFN therapy in patients with decompensated cirrhosis.
The haematological side effect includes neutropenia (50–60%), thrombocytopaenia (30–50%),
and anaemia (30–60%). There is an increased risk of infection (4–13%) or hepatic
decompensation during therapy (11–20%) [8, 9]. Carrion et al. reported high incidence of
episodes of bacterial infection, mostly spontaneous bacterial peritonitis in treated patients
(25%) compared to controls (6%) (P = 0.01) [15]. Variables independently associated with the
occurrence of bacterial infections were antiviral treatment and a Child-Pugh score of B–C. The
adverse effect of this therapy increase as the child score increase, where child C patients has
very high complication rate with extremely low response. We reported the safety and efficacy
of PEG-IFN and ribavirin therapy in 90 patients with liver cirrhosis, 18% required dose
reduction, 33% stopped treatment because of adverse effects, 9% had deterioration of liver
function, 7% died and13% of patients SVR. The rate of serious complications was 16.3% in
child's class A, 48% in B, and 100% in C (P = 0.005). Serum albumin was a significant predictor
for worsening liver function (P = 0.007), none of the child C patients achieved SVR [16].
2. New direct acting antivirals (DAAs)
Accordingly, the AASLD-IDSA guidelines consider any patient with chronic hepatitis C
infection who is diagnosed with compensated cirrhosis highest priority for hepatitis C
treatment [4].
For HCV-infected patients with decompensated cirrhosis or hepatocellular cancer, treatment
of HCV may provide benefit, but the treatment plans and goals may need modifying if the
patient is planning to undergo liver transplantation.
2.1. Patients with compensated cirrhosis
For patients with compensated cirrhosis (Child-Turcotte-Pugh Class A), including those with
hepatocellular carcinoma, the AASLD/IDSA/IAS-USA guidance [4] recommends using the
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same general treatment approach as used for patients without cirrhosis, with several key
exceptions primarily related to duration of therapy or inclusion of ribavirin.
2.1.1. Genotype 1
2.1.1.1. Ledipasvir/sofosbuvir
Ledipasvir (90 mg) and sofosbuvir (400 mg) are a fixed-dose combination (Harvoni®) of two
direct-acting antiviral agents that were initially studied in the ION-1 trial. The trial that
included 865 treatment-naïve patients, looked at the length of treatment (12 weeks versus 24
weeks) as well as the need for RBV [5]. SVR12 rates exceeded 97%, with no added benefit
observed with longer treatment duration, the addition of RBV length of treatment, nor HCV
genotype 1 subtype. In the study, 16% of the included patients had cirrhosis. The presence of
cirrhosis did not affect SVR12 rates compared with those without cirrhosis (97%) versus (98%)
[5].
2.1.1.2. Paritaprevir/ritonavir/ombitasvir + dasabuvir (PrOD)
The 3D combination was studied in the TURQUOISE-II and TURQUOISE-III trials. The trail
included 261, HCV genotype 1a and CTP class A, the patients were both treatment-naïve and
-experienced. The study compared 12 weeks or 24 weeks of PrOD regimen with the addition
of RBV. SVR12 rates were higher in patients who received 24 weeks arm (89% vs. 95%) [6].
Factors that may have contributed to these differences could be the inclusion of patients who
failed previous PEG-IFN/RBV therapy. Overall, treatment-naïve patient had slightly better
response to therapy (92% vs. 95%). Interestingly, in patients with HCV genotype 1b patient,
the SVR12 rates reached 98.5% in the 12-week arm [6]. Subsequently, the TURQUOISE-III trail
questioned the role of RBV with the 3D regimen for 12 weeks in patients with HCV genotype
1b and compensated cirrhosis. Among the 60 patients included, more than 50% of the patients
had negative predictors of response as follows: 55% treatment-experienced, 83% with IL28B
non-CC genotype, 22% had platelet counts of greater than 90 × 109 L−1, and 17% had albumin
levels greater than 3.5 g/dL). SVR12 rates were 100%. Hence, this regimen was approved for
HCV genotype 1b for 12 weeks irrespective of previous treatment history or the presence or
of cirrhosis [7].
The PrOD regimen, however, carries FDA warning [8]. In October 2015, the US FDA announced
that the PrOD and PrO are contraindicated in patients with Child-Turcotte-Pugh (CTP) class
B or C cirrhosis. This was based on reports by the manufacturer of accelerated liver injury in
patients who were receiving PrOD or PrO. The onset of liver harm and decompensating
incidents were observed mainly during the first month of therapy and mainly involved a quick
rise in total and direct bilirubin, as well as a concomitant increase in liver transaminases. Timely
recognition and termination of PrOD or PrO resulted in resolution of injury, death was reported
in two cases with compensated cirrhosis. If the decision is made to initiate treatment with PrOD
or PrO, patients should be made aware of the risks associated with such therapy in addition
to adequate monitoring.
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2.1.1.3. Simeprevir + sofosbuvir
Simiprevir + sofosbuvir regimen were studied in the OPTIMIST-2 trial. The single armed, open-
label trial looked at 12 weeks of simeprevir plus sofosbuvir in 103 cirrhotic patients [9]. SVR12
rates were 88% (44/50) of treatment-naïve and 79% (42/53) of treatment-experienced patients
with the total SVR12 rate was 83% (86/103). Furthermore, both genotype 1a and the presence
of Q80K mutation negatively affected SVR12 (genotype 1 and 1b 84% [26/31] and 92% [35/38],
respectively. And 74% [25/34] with Q80K mutation. Currently, there is no data that proves that
extending treatment, with or without the addition of RBV, will increase efficacy of these two
groups. Hence, until further data proves otherwise, this regimen should be avoided in patients
with genotype 1a or in the case Q80K mutation is present.
2.1.1.4. Daclatasvir + sofosbuvir
Cirrhotic patients tend to take advantage from extension of therapy with daclatasvir and
sofosbuvir to 24 weeks, with or without RBV [10, 11]. The data from ALLY-1 trial investigated
daclatasvir and sofosbuvir with RBV dosed at 600 mg, in 60 patients with advanced cirrhosis
[12]. Only 76% of patients with HCV genotype 1a (n = 34) and 100% of patients with HCV
genotype 1b (n = 11) achieved an SVR at 12 weeks (SVR12). It is unclear how many treatment
failures were among treatment-naïve patient was 54% or those with CTP class A cirrhosis. SVR
was significantly lower in CTP class C cirrhosis (54%) when compared with CTP classes A and
B 92% and 94% (see Table 1).
SVR12 rates in patients with Child Pugh A cirrhosis
GT1a GT1b GT2 GT3 GT4 GT5/6
SOF +SIM 12 weeks 83% (9)& NA NA NA NA NA
SOF+DAC 12 weeks 76%(12) 100%(12) NA 85.9%^(27) NA NA
SOF+DAC 24 weeks NA NA NA NA NA
SOF+LED+RBV 12 weeks 97–98%(5) NA NA NA 100% NA
SOF+LED 24 weeks NA NA NA NA NA NA
PrOD 12 weeks 98.5%^(6) 100%^(6) NA NA NA NA
PrO 12 weeks NA NA 96$(30) NA
SOF+VEL 12 99% 95% 100% 100% 100% 100%
GRZ+ELB 12 97%*(13, 14) 99% NA NA NA NA
GRZ+ELB 16 100%(15) NA NA NA NA NA
&With 88% (44/50) of treatment-naïve and 79% (42/53) of treatment-experienced patients.
^With ribavirin.
$100% SVR12 rates achieved with extending the duration to 16 weeks.
*Treatment naïve. SOF: sofosbuvir, SIM: simiprevir, DAC: daclatasvir LED: ledipasvir, PrOD: paritaprevir, ritonavir,
ombitasvir and dasabuvir. PrO: paritaprevir, ritonavir, ombitasvir. VEL: velpatasvir, GRZ: grazoprevir, ELB: elbasvir.
Table 1. SVR12 rates among HCV-infected patients with compensated cirrhosis.




For genotype 1a, recommendations for cirrhotic patients are based on 92 (22%) patients in the
phase III C-EDGE trial that had Metavir F4 disease [13]. SVR 12 was 97% in the subgroup of
cirrhotic patients. A similar 97% (28/29) SVR 12 rate had previously been demonstrated in
genotype 1 cirrhotic treatment-naïve patients treated with 12 weeks of elbasvir/grazoprevir
without ribavirin in the open-label phase II C-WORTHY trial [14]. The presence or absence of
compensated cirrhosis does not appear to alter the efficacy of the elbasvir/grazoprevir
regimen [13, 14].
The presence of NS5A resistance-associated variants (RAVs) at baseline was found to be
associated with reduced efficacy in patients with genotype 1a, and was not apparent with
genotype 1b [13]. In this phase III open-label trial of elbasvir/grazoprevir that enrolled
treatment-experienced patients; among 58 genotype 1a patients who received 16 weeks of
therapy with elbasvir/grazoprevir plus ribavirin, there were no virologic failures and the
SVR12 rates were 100% [15–17].
2.1.1.6. Sofosbuvir/velpatasvir
The use of this combination in patients with decompensated cirrhosis was investigated in the
ASTRAL-4 trial. The study was multicentre, open-label patients were randomly assigned in a
1:1:1 ratio to receive a fixed-dose combination tablet containing 400 mg of sofosbuvir and 100
mg of velpatasvir, administered orally once daily for 12 weeks; sofosbuvir-velpatasvir plus
ribavirin once daily for 12 weeks; or sofosbuvir-velpatasvir once daily for 24 weeks. Ribavirin
was administered orally with food twice daily, with the dose determined according to body
weight (1000 mg daily in patients with a body weight of greater than 75 kg and 1200 mg daily
in patients with a body weight ≥75 kg). The overall SVR12 rates in the three groups were 83,
94 and 86%, respectively. The study highlights a potential role of RBV in such population [18].
Nineteen percent of the patients included in the ASTRAL-1 study had cirrhosis and observed
SVR12 rates of 99% when received sofosbuvir/velpatasvir for 12 weeks [19].
2.1.2. Genotype 2
Sofosbuvir (400 mg daily) was combined with weight-based RBV for treatment-naïve patients
with HCV genotype 2 infection in three clinical trials, each of which enrolled patients with
HCV genotype 2 or 3: FISSION, POSITRON and VALENCE with very high SVR12 rates [20–
22]. However, patients with cirrhosis have lower response rates that were seen in treatment-
naïve patients with cirrhosis compared to in those without cirrhosis [23]. One may consider
extending treatment duration when cirrhosis is present despite the lack of data to support such
extension, as longer treatment duration is known to improve SVR in treatment-experienced
patients with cirrhosis [22, 24]. Due to the small numbers of patients with HCV genotype 2
infection and cirrhosis enrolled in the registration trials, several phase III b studies are ongoing
to specifically determine the appropriate length of treatment for this subgroup of patients (see
Table 1).
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2.1.3. Genotype 3
2.1.3.1. Sofosbuvir/daclatasvir
ALLY-3 is a phase III study of the once-daily NS5A inhibitor daclatasvir plus sofosbuvir for 12
weeks; the study included 101 treatment-naïve patients and demonstrated an SVR12 rate of
90%. Cirrhotic patients (Metavir F4), 58% achieved SVR12 [25]. Hence extension of therapy
may be considered in such cases. European compassionate use program has supported these
recommendations in cohort studies, which reported and improvement in rates of up to 70%
versus 86% when daclatasvir and sofosbuvir was used for 12 weeks and 24 weeks. RBV did
not seem to have a big impact on SVR12 (85.9% without RBV compared to 81.3% with RBV).
SVR12 rates were also higher in those with compensated Child-Pugh A cirrhosis (85–90%
compared to 70.6% in child B/C). Previous data suggested that SVR 12 rates were higher in
treatment-naïve patients (91–100%) compared to experienced (81–82%) [26].
2.1.4. Genotype 4
2.1.4.1. Ledipasvir/sofosbuvir
The SYNERGY trial was an open-label study evaluating 12 weeks of ledipasvir/sofosbuvir in
21 HCV genotype 4-infected patients, Among that 60% were treatment-naïve and 43% had
advanced fibrosis (Metavir stage F3 or F4) [27]. All patients achieved an SVR12. Note that the
study used an assay by ROCH with lower limit of quantitation (LLOQ) of 43 IU/ml, while the
AASLD guidelines recommended to use an assay with LLOQ of 25 IU/ml. However, this had
no impact on SVR12 results [28].
2.1.4.2. Paritaprevir/ritonavir/ombitasvir (PrO)
Pro regimen has interesting SVR12 rates according to the AGATE-I trial. The trial random-
ized 120 subjects with genotype 4 HCV and compensated cirrhosis to 12 weeks or 16 weeks
of paritaprevir/ritonavir/ombitasvir (PrO) in addition to weight-based ribavirin. The SVR12
rates were 96% and 100% in the 12 week and 16 week arms, respectively [29]. On the other
hand, the AGATE-II trial randomized 60 patients with compensated (1:1) to Pro for either
12 weeks or 24 weeks. SVR12 rates in the 12 weeks group were 97% versus 93% in the 24
week group [30].
2.1.4.3. Sofosbuvir/simiprevir
In a study by Moreno et al., the combination was studied in patients with advanced fibro-
sis/cirrhosis. All patients achieved end of treatment response but SVR12 data were not
available [31]. In another study by Kayali et al., the combination was found to achieve
SVR12 rates of 77% MELD scores remain unchanged. Interestingly, black gender and BMI
were identified as independent negative predictors of response in univariate regression
analysis (see Table 1) [32].
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3. Patients with decompensated cirrhosis
3.1. Sofosbuvir/ledipasvir
The SOLAR-1 study was a multicentre, randomized controlled trial of 108 patients with HCV
genotype 1 and 4 who had decompensated cirrhosis, of whom 59 were classified as CTP class
B and 49 classified as CTP class C cirrhosis. Subjects were randomly assigned to receive daily
fixed dose combination ledipasvir/sofosbuvir and RBV (initial dose of 600 mg, increased as
tolerated) for 12 or 24 weeks. Extension of treatment in cirrhotic patients did not seem to affect
SVR rates much. For CTP B patients, SVR rates were 87% versus 89% in subjects who received
12 versus 24 weeks, respectively. Likewise, the rates of SVR CTP class C subjects were 86 and
87%, respectively, with 12 and 24 weeks of antiviral therapy [33]. During the study, only one
patient with CTP class C cirrhosis died.
The SOLAR-2 study was a multicentre randomized controlled trial of 108 subjects with
decompensated cirrhosis secondary to HCV genotypes 1 and 4. Some of the patients were
treatment-experienced, with CTP class B cirrhosis or CTP class C cirrhosis. The patients were
randomly assigned to receive daily fixed-dose combination ledipasvir/sofosbuvir and RBV
(initial dose of 600 mg, increased as tolerated) for 12 weeks or 24 weeks. Sustained virologic
response (SVR) was achieved in 87% of those given the 12-week treatment course and 89% of
those given the 24-week treatment course. On the 4th week of treatment, the total bilirubin and
serum albumin levels improved compared with baseline in all patients. Despite the fact that
some patients experienced worsening of hepatic function, baseline CTP and model for end-
stage liver disease (MELD) scores improved in more than 50% of the treated patients. Five
patients died during the study period but none of the death occurred was attributed to the
study medication. Adverse events were more common in the 24-week arm (34%) than in the
12-week arm (15%). These results indicate that a 12-week course of ledipasvir/sofosbuvir and
RBV (initial dose of 600 mg, increased as tolerated) is an appropriate regimen for patients with
decompensated cirrhosis who are infected with HCV genotype 1 or 4. Such therapy may lead
to objective improvements in hepatic function and reduce the likelihood of recurrent HCV
infection after subsequent transplantation [33].
3.2. Sofosbuvir/daclatasvir
Patients with advanced cirrhosis (Child-Turcotte-Pugh [CTP] class B and C; n = 60) were
particularly investigated in the ALLY-1 study [34]. The study found the use of daclatasvir (60
mg daily) with sofosbuvir (400 mg) and low initial dose of RBV (600 mg) for 12 weeks to
treatment-naïve and -experienced patients with HCV genotype 1 infection. The overall SVR12
rate was 83% among those with advanced cirrhosis. The SVR12 rate was slightly lower in
patients with genotype 1a compared with patients with genotype 1b (76 and 100%, respec-
tively). Response rates were also affected by severity of disease among those with advanced
cirrhosis (94% SVR12 rates in patients with CTP class B and 56% in patients with CTP class C).
Patients with genotype 3 had also lower SVR12 rates 83%.
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In another real-world study by Foster et al., involving 235 genotype 1 patients with decom-
pensated cirrhosis, the SVR rates were comparable in the genotype 1 subjects (n = 235) receiving
SOF/LDV/RBV or SOF/LDV (86% vs. 81%) and those receiving SOF/DCV/RBV or SOF/DCV
therapy (82–60%). In this study, 91% of the patients received ribavirin with 20% requiring a
RBV dose reduction and only 6% discontinued RBV. Improvement in MELD scores was
observed in 42% of treated patients and worsening occurred in 11%. Moreover, 14 deaths
occurred with relatively higher incidence of SAE (26%) but none were attributed to study
medication.
3.3. Genotype 2 and 3
A multicentre, compassionate use study included 101 genotype 3 patients to be treated with
daclatasvir (60 mg), sofosbuvir (400 mg) ± RBV for 24 weeks [35]. Of those, 81% had CTP class
B cirrhosis, the MELD score was higher than15 in 16%, and 7% were post-liver transplant. The
reported SVR 12 data has demonstrated an SVR of 85–100%. Two patients died while 22
patients had an SAE and therapy was discontinued in five subjects. Summary of SVR in Child
B and C (Table 2).
SVR12 rates in patients with Child Pugh B and/or C cirrhosis
GT1a GT1b GT2 GT3 GT4 GT5/6
SOF +SIM 12 weeks NA NA NA NA NA NA
SOF+DAC 12 weeks 76%*(35) 100%(35) NA 83%(35) NA NA
SOF+DAC 24 weeks NA NA 85% (36) NA NA
SOF+LED+RBV 12 weeks 87%(34) NA NA NA NA NA
SOF+LED +RBV 24 weeks 89%(34) NA NA NA NA NA
SOF+VEL 12 88 89 100 50 100 NA
SOF+VEL+RBV 12 94 100 100 85 100 NA
SOF+VEL 24 93 88 75 50 100 100
*SVR12 rate was 94% among patients with CTP class B cirrhosis but only 56% among patients with CTP class C
cirrhosis.
SOF: sofosbuvir, SIM: simiprevir, DAC: daclatasvir, LED: ledipasvir, PrOD: paritaprevir, ritonavir, ombitasvir and
dasabuvir. PrO: paritaprevir, ritonavir, ombitasvir. VEL: velpatasvir, GRZ: grazoprevir, ELB: elbasvir.
Table 2. SVR12 rates in patients with Child Pugh B and/or C cirrhosis.
4. Summary
There is a remarkable advance in treatment of HCV in the recent few years allowing an
excellent result in difficult to treat patients with liver cirrhosis with good safety profile.
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Treating HCV in patients with liver cirrhosis is a high priority to prevent decompensation and
prevent HCV recurrence after liver transplantation.
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